Real-World Study of Adebrelimab Safety and Effectiveness in Adults with Advanced Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the safety and effectiveness of adebrelimab, a PD-L1 inhibitor, in treating patients with advanced small cell lung cancer SCLC under real-world conditions. This observational study focuses on understanding how adebrelimab works in daily practice, particularly monitoring the incidence of serious immune-related side effects. The study also aims to observe overall survival, progression-free survival, response rates, and disease control in these patients, while considering factors like brain or liver metastases and biomarkers. Participants receiving adebrelimab will be monitored for safety starting from the beginning of their treatment and continuing until 90 days after their last dose. The study tracks various outcomes for up to 12 months from enrollment, including survival rates and treatment responses. It also examines immune cell changes in the blood over three months. This approach helps gather valuable information about adebrelimabs performance in different patient groups, including elderly individuals and those with other health conditions. During the study, patients safety is closely observed through monitoring immune-related adverse events and other side effects. Researchers will collect data on survival and disease progression at regular intervals over one year. Blood samples will be taken to assess immune cells before and after treatment. The studys total duration for each patient varies but includes ongoing safety checks for three months post-treatment. This comprehensive follow-up aims to provide a clear picture of adebrelimabs impact in routine clinical use.

A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC